Development of Lactobacillus sporogenes Resistant to Rifampicin an Antituberculosis Agent

항결핵제, 리팜피신에 내성인 유산균 Lactobacillus sporogenes의 개발

Lactobacillus sporogenes was treated with N-methyl-N'-nitro-N-nitrosoguanidine (NTG) to obtain resistant mutants to rifampicin. Fifty-eight strains of the NTG-induced mutants showed distinct resistance to rifampicin and nine mutants were selected for further studies. They also exhibited identical characteristics with the parent Lactobacillus sporogenes when they were tested for spore formation, acid formation and growth inhibition of E. coli. From in vitro test it was identified that rifampicin is not inactivated by certain factors of the rifampicin resistant mutants. It is suggested that they can be utilized as efficient normalizing agents for human intestinal flora when they are simultaneously taken with rifampicin

Lactobacillus sporogenes를 NTG로 처리하여 rifampicin에 내성인 돌연변이 균주를 얻었으며, 이중 58 종이 rifampicin에 현저한 내성을 보였다. 9종의 mutants를 선발하여 그 생화학적 특성을 검토한 결과, 포자형성능, 산생성능, E. coli 생육억제능 면엣 parent와 유사한 특성을 나타내었다. In vitro 시험을 통해ㅐ, 내성균주들에 의해 rifampicin이 불활성화 되지 않음이 밝혀졌다. 따라서 이들 mutants를 유산균 제제원으로 사용할 수 있으며, 그 제제는 rifampicin과 병용투여시, 효과적인 정장제로 사용될 수 있을 것으로 사료된다.